Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Talactoferrin fails to improve progression-free or overall survival in randomized trial vs. placebo
Author
Howard (Jack) West, MD

I was disappointed to learn today that the FORTIS-M trial, a study of 720 patients with previously treated advanced NSCLC randomized to receive talactoferrin-alpha (TLF) or placebo, was reported as being negative in a press release late yesterday.   The primary endpoint was overall survival, and not only was the study quite negative for any improvement in survival (median 7.5 months with talactoferrin vs. 7.7 months on placebo arm), it also demonstrated no improvement in progression-free survival.

We haven't received any additional details, and perhaps there will be a subset identified for further study, but officials from the company indicated that they're likely to be shutting down research on it and cutting their losses.  The stock for Agennix, the manufacturers of TLF, dropped nearly 80% over the course of the last day, so this may well shut down the company.

Of course, I'm disappointed on several levels.  Not only was I truly very hopeful about this agent, partly because of its efficacy in phase II trials and partly because of its extremely favorable tolerability (it actually seems to reduce side effects when paired with chemo, compared with chemo alone).  Although I'd hope to see results of a trial of chemo + TLF vs. chemo + placebo, it seems that's unlikely to happen.

What went wrong?  The best answer is that I don't know, and I don't think anyone does.  It may be that this is just one of too many agents that looked very promising in early work, but once the larger trials more carefully tested it and held it up to higher scrutiny, it didn't live up to that promise.  I must admit that TLF got a fair test in the form of a 720 patient randomized trial that appears to not show any hint of benefit (as far as we know from a press release; the full data should be presented at a meeting in the next couple of months).  

I'm quite saddened that an agent I was pretty hopeful about fail to emerge as a new effective treatment for lung cancer, but there are others out there.

Next Previous link

Previous PostNext Post

Related Content

Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.
Image
Rare cancers
Video
In these videos,  Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.  To watch the complete playlist, click here.  
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Recent Comments

JOIN THE CONVERSATION
Hi Hopish hope,  Welcome to…
By JanineT GRACE … on
Yes, it's crucial to discuss…
By JanineT GRACE … on
Definitely a good idea to…
By OakleeFarnick on